Statistical Analysis Plan Study Code D419EC00001 Edition Number 4.0 Date 19Apr2023 Phase I/II, Open -Label, Multicenter Study to Evaluate the Safety , Tolerability and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients with Advanced Solid T umors and Hematological Malignancies Statistical Analysis Plan Study Code D419EC00001 Edition Number 4.0 Date 19Apr2023 CONFIDENTIAL AND PROPRIETARY 2of 65TABLE OF CONTENTS TITLE PAGE ........................................................................................................................ 1 TABLE OF CONTENTS ......................................................................................................